see also:

• heart failure with reduced ejection fraction (HFrEF)

• soluble guanylate cyclase stimulators are a class of therapeutic agents that increase intracellular cyclic GMP (cGMP) levels, leading to smooth muscle relaxation and improved blood flow by targeting the nitric oxide-sGC-cGMP pathway via directly stimulating the sGC enzyme independently of nitric oxide (NO) and sensitize sGC to existing NO

• directly stimulating the sGC enzyme independently of nitric oxide (NO) and sensitize sGC to existing NO leading to smooth muscle relaxation and vasodilatation
• act specifically on the reduced (ferrous) heme group of the sGC enzyme, separating them from “sGC activators” which target oxidized or heme-free enzymes
• potential side effects include hypotension, dizziness, and gastrointestinal issues

• vericiguat
  • used in heart failure with reduced ejection fraction (HFrEF)
• riociguat
  • used in pulmonary HT